Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0167
Source ID: NCT02848131
Associated Drug: Group 2: Dasatinib
Title: Senescence in Chronic Kidney Disease
Acronym:
Status: ENROLLING_BY_INVITATION
Study Results: NO
Results:
Conditions: Chronic Kidney Disease
Interventions: DRUG: Group 2: Dasatinib|DRUG: Group 2: Quercetin
Outcome Measures: Primary: Change in proportion of senescent cells (representing the total senescent cell burden) present, Assessment of senescence markers in skin, fat, and/or blood at baseline and day 14., Baseline, Day 14 | Secondary: Change in proportion of senescent mesenchymal stem cells present, Assessment of senescence markers in mesenchymal stem cells at baseline and day 14., Baseline, Day 14|Change in mesenchymal stem cell function, Assessment of functional studies in mesenchymal stem cells at baseline and day 14. Number of subjects with change in stem cell function related to treatment., Baseline, Day 14|Change in Frailty index score, Assessment by Fried and other frailty criteria at baseline and day 14., Baseline, Day 14|Change in kidney function, Assessment by estimated and measured glomerular filtration rate at baseline, day 14, month 4, and month 12., Baseline, Day 14, Month 4, Month 12
Sponsor/Collaborators: Sponsor: Mayo Clinic
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 30
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2016-07
Completion Date: 2025-04
Results First Posted:
Last Update Posted: 2024-04-19
Locations: Mayo Clinic Florida, Jacksonville, Florida, 32224, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States
URL: https://clinicaltrials.gov/show/NCT02848131

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D368 Dasatinib small molecule DB01254 Details